Medtronic plc
MDTMedtronic plc is a global leader in medical technology, specializing in medical devices, therapies, and solutions for various chronic diseases. Founded in 1949 and headquartered in Ireland, the company develops products for areas such as cardiac and vascular care, diabetes management, neurological disorders, and surgical equipment, aiming to improve patient outcomes and healthcare efficiency worldwide.
Dividend History
Investors can expect a dividend payout of $0.71 per share, scheduled to be distributed in 10 days on January 16, 2026
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| January 16, 2026 | $0.71 | 2025-12-26 | 2025-12-26 |
| October 17, 2025 | $0.71 | 2025-09-26 | 2025-09-26 |
| July 11, 2025 | $0.71 | 2025-06-27 | 2025-06-27 |
| April 11, 2025 | $0.70 | 2025-03-28 | 2025-03-28 |
| January 10, 2025 | $0.70 | 2024-12-27 | 2024-12-27 |
Dividends Summary
- Medtronic plc has issued 88 dividend payments over the past 22 years
- The most recent dividend was paid 81 days ago, on October 17, 2025
- The highest dividend payed out to investors during this period was $0.71 per share
- The average dividend paid during this period was $0.38 per share.
Company News
The article recommends Costco and Intuitive Surgical as long-term growth stocks suitable for 20-year holding periods. Costco has risen 430% over the past decade through its membership-based model, while Intuitive Surgical's da Vinci surgical robots have gained 825% with strong demand and recurring revenue from parts and services. Both stocks trad...
The FDA classified Medtronic's Left Heart Vent Catheter recall as Class I, the most serious category, due to defects that may cause the device to fail to hold its shape during cardiopulmonary bypass procedures. The malfunction could result in tissue abrasion, perforation, or death. As of July 28, three serious injuries have been reported with no ...
The transcatheter heart valve replacement market is projected to grow from $6.40 billion in 2025 to $19.98 billion by 2033, with a 15.32% CAGR, driven by rising valvular heart disease prevalence and preference for minimally invasive cardiac procedures.
Medtronic's stock is showing positive momentum after a strong Q2 performance, with potential for 20-30% price appreciation driven by mid-single-digit growth, healthy margins, and consistent capital returns.
Medtronic's (MDT) stock suffers as a result of geopolitical complications and supply issues despite an expanding portfolio and strong strategic executions.
